Sarepta Therapeutics ( NASDAQ: SRPT) was upgraded to Neutral from Underweight at J.P. Morgan as it sees FDA's Elevidys hold removal recommendation in ambulatory patients as a clear win.

This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...

Analysts’ view on the stock has dramatically changed over the past few months. Currently, only 21% of the 29 analysts ...

Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and ...

It has been a tumultuous two weeks for Sarepta; however, the FDA reauthorising US shipments of Elevidys will be a welcome development.

Despite all the buzz around Sarepta and concerns about Elevidys, industry watchers aren’t convinced this current controversy ...

"This was primarily driven by 18% growth seen from the oncology portfolio, which has done well as a result of key drugs such ...

Sarepta Therapeutics said on Monday it will resume shipping of its gene therapy Elevidys to patients with a rare muscular ...

FDA recommends lifting the hold on Sarepta's gene therapy Elevidys for ambulatory patients after investigation; ...

Wall Street traders left stocks at all-time highs while the dollar climbed the most since May, with a tariff deal between ...

What Happened? Shares of life sciences company Revvity (NYSE:RVTY) fell 7.6% in the afternoon session after the company ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $100 million milestone payment from ...